Daiichi Sankyo Reports the Commercial Availability of Vanflyta (quizartinib) in the US for Newly Diagnosed FLT3-ITD Positive AML
Shots:
- The company launches Vanflyta, the first & only FLT3 inhibitor in the US for newly diagnosed FLT3-ITD+ AML. Vanflyta was approved in the US on July 2023 in combination with standard cytarabine, anthracycline induction & cytarabine consolidation, and as maintenance monotx. following consolidation CT
- The P-III (QuANTUM-First) trial results showed that patients treated with combination therapy achieved a 22% reduction in risk of death vs standard CT alone, CR rates were similar b/w both arms, median duration of CR (38.6 vs 12.4mos.)
- The therapy also provides a new, effective & generally well-tolerated treatment option for patients & the results were published in The Lancet. Vanflyta was also approved in Japan for AML i.e., FLT3-ITD mutation-positive
Ref: Daiichi | Image: Daiichi
Related News:- Daiichi Sankyo’s Vanflyta Receives the US FDA’s Approval for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
